David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University, talks about the first-in-human trial of interneuron cell therapy for treatment of focal epilepsy and explains the next steps.
The first phase of a first-in-human trial of NRTX-1001, an intraneuron cell therapy treatment for epilepsy, focused on safety, and next will come a randomized, controlled trial to assess efficacy, according to David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University.
Transcript
How long is the clinical trial for interneuron cell therapy for treatment of focal epilepsy, and what are the next steps if it proves to be successful?
The cell therapy approach for treating epilepsy that we're exploring is a major commitment to the participants who've taken a big step to join into this study. It's a long-term approach. From the perspective of a person entering into the trial, the main part of the study lasts 2 years, but there's an extension study that continues beyond that for up to 15 years, where we'll continue to follow people and track their outcomes.
From the perspective of the overall study, It has 2 phases. The first phase we’re especially focusing on the safety of doing the cell implants, and so we're going at a cautious pace. After the first implant was completed last June, there was a waiting period, there was a lot of safety assessments and a committee met to ensure that the outcome looks good in that person before we moved on to doing an implant in the second person, which was in last fall of 2022. We're anticipating 5 participants receiving the cell implants, another pause in assessments, a second 5 potentially at a higher dose of cells.
And then at that point in the trial, we'll shift into a hybrid approach continuing to look at safety, but also looking more closely at efficacy. The second phase will be a small, randomized controlled trial, so some people will get cell therapy initially, others will get delayed therapy, and we'll try to look very carefully at the responses that are very specific to cell implants.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More